Comparative effectiveness and cost-effectiveness of cardioprotective glucose-lowering therapies for type 2 diabetes in Brazil: a Bayesian network model
Nogueira A, Barreto J, Moura F, Luchiari B, Abuhab A, Bonilha I, Nadruz W, Gaziano J, Gaziano T, de Carvalho L, Sposito A. Comparative effectiveness and cost-effectiveness of cardioprotective glucose-lowering therapies for type 2 diabetes in Brazil: a Bayesian network model. Health Economics Review 2023, 13: 50. PMID: 37878108, PMCID: PMC10599033, DOI: 10.1186/s13561-023-00466-3.Peer-Reviewed Original ResearchIncremental cost-effectiveness ratioGlucose-lowering therapyType 2 diabetesNetwork meta-analysisSecondary preventionPrevalence of type 2 diabetesBrazilian public health systemRisk of cardiovascular outcomesPublic health systemCost-effectiveReduced relative riskNon-fatal cardiovascular eventsContext of primary preventionConclusionsIn BrazilClasses of glucose-lowering therapiesHealth systemManagement of T2DMGLP-1aCost-effectiveness modelStandard carePrimary preventionCost-effectiveness ratioRelative riskEvidence-basedInternational dollars